New Data Show LEO Pharma’s Kyntheum® (brodalumab) Provides Greater Probability of Achieving Complete Skin Clearance for People with Moderate to Severe Psoriasis Compared with ustekinumab

Possibility of complete clearance of psoriasis symptoms can have a transformational impact on happiness, according to a new European survey of more than 7,000 people living with the disease.

*** THIS MATERIAL IS NOT INTENDED FOR FRENCH JOURNALISTS ***

BALLERUP, Denmark--(BUSINESS WIRE)--Data presented at the 27^th European Academy of Dermatology and Venereology (EADV) in Paris, show that treatment with LEO Pharma’s Kyntheum^® (brodalumab) for people with moderate to severe plaque psoriasis, was associated with a more rapid reduction in absolute Psoriasis Area Severity Index (PASI) scores and a greater probability of achieving complete skin clearance in all body regions compared with ustekinumab.^1,2 The possibility of attaining completely clear skin makes a significant difference to the lives of people with psoriasis, according to the newly published PsoClear Report.³

Outcomes of the first of two analyses of pooled data from the AMAGINE-2 and AMAGINE-3 studies showed a greater proportion of those taking Kyntheum^® achieved (absolute) PASI 0, meaning complete skin clearance without any symptoms of psoriasis, over time compared with ustekinumab (75% versus 52%, respectively at 52 weeks).¹ Absolute PASI scores measure the severity of redness, thickness and scaling of skin on different parts of the body, whereby a score of less than three is indicative of treatment success.⁴ Results of the second analysis found that the time it took for 50% of patients to achieve complete clearance across all body regions – head and neck, trunk, upper limbs and lower limbs – was shorter with Kyntheum^® than ustekinumab. Over the course of the 52-week analysis, superior rates of complete clearance were seen as early as week two for Kyntheum^® treated patients.² Please see the full press release attached.